|
|
Breast Cancer Cure - Breast Cancer Medicine Drug
Breast cancer is a cancer that starts in the cells of the breast.[1] Worldwide, breast cancer is the second most common type of cancer after lung cancer (10.4% of all cancer incidence, both sexes counted)[2] and the fifth most common cause of cancer death.[3] However, among women worldwide, breast cancer is by far the most common cause of cancer, both in incidence and death.[3] In 2005, breast cancer caused 502,000 deaths worldwide (7% of cancer deaths; almost 1% of all deaths).[3] The number of cases worldwide has significantly increased since the 1970s, a phenomenon partly blamed on modern lifestyles in the Western world.[4][5]
Breast cancer incidence is much higher in the Western world, whether in Europe or North America, than in third world countries. North American women have the highest incidence of breast cancer in the world.[6] Among women in the U.S., breast cancer is the most common cancer and the second-most common cause of cancer death (after lung cancer).[6] Women in the U.S. have a 1 in 8 (12.5%) lifetime chance of developing invasive breast cancer and a 1 in 35 (3%) chance of breast cancer causing their death.[6] In 2007, breast cancer was expected to cause 40,910 deaths in the U.S. (7% of cancer deaths; almost 2% of all deaths).[7]
In the U.S., both incidence and death rates for breast cancer have been declining in the last few years.[8][7] Nevertheless, a U.S. study conducted in 2005 by the Society for Women's Health Research indicated that breast cancer remains the most feared disease,[9] even though heart disease is a much more common cause of death among women.[10]
Because the breast is composed of identical tissues in males and females, breast cancer also occurs in males.[11][12] Incidences of breast cancer in men are approximately 100 times less common than in women, but men with breast cancer are considered to have the same statistical survival rates as women.[13]
Contents [hide] 1 Classification 1.1 Pathologic types 2 Signs and symptoms 3 Epidemiology and etiology 4 Prevention 4.1 Phytoestrogens and soy 4.2 Folic acid (folate) 4.3 Avoiding exposure to secondhand tobacco smoke 4.4 Oophorectomy and mastectomy 4.5 Medications 4.5.1 Selective estrogen receptor modulators (SERMs) 5 Screening 5.1 X-ray mammography 5.2 Criticisms of screening mammography 5.2.1 Mammography in women less than 50 years old 5.3 Enhancements to mammography 5.4 Breast MRI 5.5 Breast self-exam 5.6 Genetic testing 6 Diagnosis 7 Staging 8 Treatment 9 Prognosis 9.1 Psychological aspects of diagnosis and treatment 9.2 Racial disparities in diagnosis and treatment 10 Metastasis 11 History 12 Cultural references 13 See also 14 References 15 External links
[edit] Classification It has been suggested that this section be split into a new article. (Discuss)
Time line of breast cancer suggesting probable heterogeneity. Primary breast cancers begin as single (or more) cells which have lost normal regulation of differentiation and proliferation but remain confined within the basement membrane of the duct or lobule. As these cells go through several doublings, at some point they invade through the basement membrane of the duct or lobule and ultimately metastasize to distant organs.[14]Breast cancers are described along four different classification schemes, or groups, each based on different criteria and serving a different purpose :
Pathology - A pathologist will categorize each tumor based on its histological (microscopic anatomy) appearance and other criteria. The most common pathologic types of breast cancer are invasive ductal carcinoma, malignant cancer in the breast's ducts, and invasive lobular carcinoma, malignant cancer in the breast's lobules. Grade of tumor - The histological grade of a tumor is determined by a pathologist under a microscope. A well-differentiated (low grade) tumor resembles normal tissue. A poorly differentiated (high grade) tumor is composed of disorganized cells and, therefore, does not look like normal tissue. Moderately differentiated (intermediate grade) tumors are somewhere in between. Protein & gene expression status - Currently, all breast cancers should be tested for expression, or detectable effect, of the estrogen receptor (ER), progesterone receptor (PR) and HER2/neu proteins. These tests are usually done by immunohistochemistry and are presented in a pathologist's report. The profile of expression of a given tumor helps predict its prognosis, or outlook, and helps an oncologist choose the most appropriate treatment. More genes and/or proteins may be tested in the future. Stage of a tumour - The currently accepted staging scheme for breast cancer is the TNM classification : Tumor - There are five tumor classification values (Tis, T1, T2, T3 or T4) which depend on the presence or absence of invasive cancer, the dimensions of the invasive cancer, and the presence or absence of invasion outside of the breast (e.g. to the skin of the breast, to the muscle or to the rib cage underneath). Lymph Node - There are four lymph node classification values (N0, N1, N2 or N3) which depend on the number, size and location of breast cancer cell deposits in lymph nodes. Metastases - There are two metastatic classification values (M0 or M1) which depend on the presence or absence of breast cancer cells in locations other than the breast and lymph nodes (so-called distant metastases, e.g. to bone, brain, lung).
[edit] Pathologic types The latest (2003) World Health Organization (WHO) classification of tumors of the breast[15] recommends the following pathological types:
Invasive breast carcinomas
Invasive ductal carcinoma Most are "not otherwise specified" The remainder are given subtypes: Mixed type carcinoma Pleomorphic carcinoma Carcinoma with osteoclastic giant cells Carcinoma with choriocarcinomatous features Carcinoma with melanotic features Invasive lobular carcinoma Tubular carcinoma Invasive cribriform carcinoma Medullary carcinoma Mucinous carcinoma and other tumours with abundant mucin Mucinous carcinoma Cystadenocarcinoma and columnar cell mucinous carcinoma Signet ring cell carcinoma Neuroendocrine tumours Solid neuroendocrine carcinoma (carcinoid of the breast) Atypical carcinoid tumour Small cell / oat cell carcinoma Large cell neuroendocrine carcioma Invasive papillary carcinoma Invasive micropapillary carcinoma Apocrine carcinoma Metaplastic carcinomas Pure epithelial metaplastic carciomas Squamous cell carcinoma Adenocarcinoma with spindle cell metaplasia Adenosquamous carcinoma Mucoepidermoid carcinoma Mixed epithelial/mesenchymal metaplastic carcinomas Lipid-rich carcinoma Secretory carcinoma Oncocytic carcinoma Adenoid cystic carcinoma Acinic cell carcinoma Glycogen-rich clear cell carcinoma Sebaceous carcinoma Inflammatory carcinoma Bilateral breast carcinoma Mesenchymal tumors (including sarcoma)
Haemangioma Angiomatosis Haemangiopericytoma Pseudoangiomatous stromal hyperplasia Myofibroblastoma Fibromatosis (aggressive) Inflammatory myofibroblastic tumour Lipoma Angiolipoma Granular cell tumour Neurofibroma Schwannoma Angiosarcoma Liposarcoma Rhabdomyosarcoma Osteosarcoma Leiomyoma Leiomysarcoma Precursor lesions
Lobular neoplasia lobular carcinoma in situ Intraductal proliferative lesions Usual ductal hyperplasia Flat epithelial hyperplasia Atypical ductal hyperplasia Ductal carcinoma in situ Microinvasive carcinoma Intraductal papillary neoplasms Central papilloma Peripheral papilloma Atypical papilloma Intraductal papillary carcinoma Intracystic papillary carcinoma Benign epithelial lesions
Adenosis, includin variants Sclerosing adenosis Apocrine adenosis Blunt duct adenosis Microglandular adenosis Adenomyoepithelial adenosis Radial scar / complex sclerosing lesion Adenomas Tubular adenoma Lactating adenoma Apocrine adenoma Pleomorphic adenoma Ductal adenoma Myoepithelial lesions
Myoepitheliosis Adenomyoepithelial adenosis Adenomyoepithelioma Malignant myoepithelioma Fibroepithelial tumours
Fibroadenoma Phyllodes tumour Benign Borderline Malignant Periductal stromal sarcoma, low grade Mammary hamartoma Tumours of the nipple
Nipple adenoma Syringomatous adenoma Paget's disease of the nipple Malignant lymphoma
Metastatic tumours
Tumours of the male breast
Gynecomastia Carcinoma In situ Invasive
The classifications above show that breast cancer is usually, but not always, classified by its histological appearance. Rare variants are defined on the basis of physical exam findings. For example, Inflammatory breast cancer (IBC), a form of ductal carcinoma or malignant cancer in the ducts, is distinguished from other carcinomas by the inflamed appearance of the affected breast.[16] In the future, some pathologic classifications may be changed. For example, a subset of ductal carcinomas may be re-named basal-like carcinoma (part of the "triple-negative" tumors).[citation needed]
[edit] Signs and symptoms The first symptom, or subjective sign, of breast cancer is typically a lump that feels different than the surrounding breast tissue. According to the Merck Manual, greater than 80% of breast cancer cases are discovered as a lump by the woman herself.[17] According to the American Cancer Society (ACS), the first medical sign, or objective indication of breast cancer as detected by a physician, is discovered by mammogram.[7] Lumps found in lymph nodes located in the armpits[17] and/or collarbone[citation needed] can also indicate breast cancer.
Indications of breast cancer other than a lump may include changes in breast size or shape, skin dimpling, nipple inversion, or spontaneous single-nipple discharge. Pain is an unreliable tool in determining the presence of breast cancer, but may be indicative of other breast-related health issues such as mastodynia.[7][17][18]
When breast cancer cells invade the dermal lymphatics, small lymph vessels in the skin of the breast, its presentation can resemble skin inflammation and thus is known as inflammatory breast cancer (IBC). Symptoms of inflammatory breast cancer include pain, swelling, warmth and redness throughout the breast, as well as an orange peel texture to the skin referred to as peau d'orange.[17]
Another reported symptom complex of breast cancer is Paget's disease of the breast. This syndrome presents as eczematoid skin changes such as redness and mild flaking of the nipple skin. As Paget's advances, symptoms may include tingling, itching, increased sensitivity, burning, and pain. There may also be discharge from the nipple. Approximately half of women diagnosed with Paget's also have a lump in the breast.[19]
Occasionally, breast cancer presents as metastatic disease, that is, cancer that has spread beyond the original organ. Metastatic breast cancer will cause symptoms that depend on the location of metastasis. More common sites of metastasis include bone, liver, lung and brain. Unexplained weight loss can occasionally herald an occult breast cancer, as can symptoms of fevers or chills. Bone or joint pains can sometimes be manifestations of metastatic breast cancer, as can jaundice or neurological symptoms. These symptoms are "non-specific," meaning they can also be manifestations of many other illnesses.[20]
Most symptoms of breast disorder do not turn out to represent underlying breast cancer. Benign breast diseases such as mastitis and fibroadenoma of the breast are more common causes of breast disorder symptoms. The appearance of a new symptom should be taken seriously by both patients and their doctors, because of the possibility of an underlying breast cancer at almost any age.[21]
[edit] Epidemiology and etiology Main article: Epidemiology and etiology of breast cancer Epidemiological risk factors for a disease can provide important clues as to the etiology, or cause, of a disease. The first case-controlled study on breast cancer epidemiology was done by Janet Lane-Claypon, who published a comparative study in 1926 of 500 breast cancer cases and 500 control patients of the same background and lifestyle for the British Ministry of Health.[22][verification needed][23]
Today, breast cancer, like other forms of cancer, is considered to be the final outcome of multiple environmental and hereditary factors. Some of these factors include:
Lesions to DNA such as genetic mutations. Mutations that can lead to breast cancer have been experimentally linked to estrogen exposure.[24] Beyond the contribution of estrogen, research has implicated viral oncogenesis and the contribution of ionizing radiation in causing genetic mutations.[citation needed] Failure of immune surveillance, a theory in which the immune system removes malignant cells throughout ones life.[25] Abnormal growth factor signaling in the interaction between stromal cells and epithelial cells can facilitate malignant cell growth. For example, tumors can induce blood vessel growth (angiogenesis) by secreting various growth factors further facilitating cancer growth.[citation needed] Inherited defects in DNA repair genes, such as BRCA1, BRCA2[26] and p53.[citation needed] Although many epidemiological risk factors have been identified, the cause of any individual breast cancer is often unknowable. In other words, epidemiological research informs the patterns of breast cancer incidence across certain populations, but not in a given individual. The primary risk factors that have been identified are sex,[27] age,[28] childbearing, hormones,[29] a high-fat diet,[30] alcohol intake,[31] obesity,[32] and environmental factors such as tobacco use and radiation.[26]
No etiology is known for 95% of breast cancer cases, while approximately 5% of new breast cancers are attributable to hereditary syndromes.[33] In particular, carriers of the breast cancer susceptibility genes, BRCA1 and BRCA2, are at a 30-40% increased risk for breast and ovarian cancer, depending on in which portion of the protein the mutation occurs.[34]
[edit] Prevention
[edit] Phytoestrogens and soy Phytoestrogens such as found in soybeans have been extensively studied in animal and human in-vitro and epidemiological studies. The literature support the following conclusions:
Plant estrogen intake, such as from soy products, in early adolescence may protect against breast cancer later in life.[35] Plant estrogen intake later in life is not likely to influence breast cancer incidence either positively or negatively.[36]
[edit] Folic acid (folate) Main article: Folic acid#Folic acid and cancer The factual accuracy of this article is disputed. Please see the relevant discussion on the talk page.(March 2008)
Studies have found that "folate intake counteracts breast cancer risk associated with alcohol consumption"[37] and "women who drink alcohol and have a high folate intake are not at increased risk of cancer."[38][39][40] A prospective study of over 17,000 women found that those who consume 40 grams of alcohol (about 3-4 drinks) per day have a higher risk of breast cancer. However, in women who take 200 micrograms of folate (folic acid or Vitamin B9) every day, the risk of breast cancer drops below that of alcohol abstainers.[41]
Folate is involved in the synthesis, repair, and functioning of DNA, the body’s genetic map, and a deficiency of folate may result in damage to DNA that may lead to cancer.[42] In addition to breast cancer, studies have also associated diets low in folate with increased risk of pancreatic, and colon cancer.[43][44]
Foods rich in folate include citrus fruits, citrus juices, dark green leafy vegetables (such as spinach), dried beans, and peas. Vitamin B9 can also be taken in a multivitamin pill.
[edit] Avoiding exposure to secondhand tobacco smoke Breathing secondhand smoke increases breast cancer risk by 70% in younger, primarily premenopausal women. The California Environmental Protection Agency has concluded that passive smoking causes breast cancer[45] and the US Surgeon General[46] has concluded that the evidence is "suggestive," one step below causal. There is some evidence that exposure to tobacco smoke is most problemmatic between puberty and first childbirth. The reason that breast tissue appears most sensitive to chemical carcinogens in this phase is that breast cells are not fully differentiated until lactation.[47]
[edit] Oophorectomy and mastectomy Prophylactic oophorectomy (removal of ovaries), in high-risk individuals, when child-bearing is complete, reduces the risk of developing breast cancer by 60%, as well as reducing the risk of developing ovarian cancer by 96%.[48]
[edit] Medications Hormonal therapy has been used for chemoprevention in individuals at high risk for breast cancer. In 2002, a clinical practice guideline by the US Preventive Services Task Force (USPSTF) recommended that "clinicians discuss chemoprevention with women at high risk for breast cancer and at low risk for adverse effects of chemoprevention" with a grade B recommendation.[49][verification needed][50][51]
[edit] Selective estrogen receptor modulators (SERMs) The guidelines[clarify] were based on studies of SERMs from the MORE, BCPT P-1, and Italian trials. In the MORE trial, the relative risk reduction for raloxifene was 76%.[52] The P-1 preventative study demonstrated that tamoxifen can prevent breast cancer in high-risk individuals. The relative risk reduction was up to 50% of new breast cancers, though the cancers prevented were more likely estrogen-receptor positive (this is analogous to the effect of finasteride on the prevention of prostate cancer, in which only low-grade prostate cancers were prevented).[53][54] The Italian trial showed benefit from tamoxifen.[55]
Additional randomized controlled trials have been published since the guidelines. The IBIS trial found benefit from tamoxifen.[56] In 2006, the NSABP STAR trial demonstrated that raloxifene had equal efficacy in preventing breast cancer compared with tamoxifen, but that there were fewer side effects with raloxifene.[57] The RUTH Trial concluded that "benefits of raloxifene in reducing the risks of invasive breast cancer and vertebral fracture should be weighed against the increased risks of venous thromboembolism and fatal stroke".[58] On September 14, 2007, the US Food and Drug Administration approved raloxifene (Evista) to prevent invasive breast cancer in postmenopausal women.[59]
[edit] Screening Main article: Breast cancer screening Breast cancer screening is an attempt to find unsuspected cancers. The most common screening methods are self and clinical breast exams, x-ray mammography, and breast Magnetic resonance imaging (MRI)
[edit] X-ray mammography Mammography is still the modality of choice for screening of early breast cancer, since it is relatively fast, reasonably accurate, and widely available in developed countries.
Due to the high incidence of breast cancer among older women, screening is now recommended in many countries. Recommended screening methods include breast self-examination and mammography. Mammography has been estimated to reduce breast cancer-related mortality by 20-30%.[60] Routine (annual) mammography of women older than age 40 or 50 is recommended by numerous organizations as a screening method to diagnose early breast cancer and has demonstrated a protective effect in multiple clinical trials.[61] The evidence in favor of mammographic screening comes from eight randomized clinical trials from the 1960s through 1980s. Many of these trials have been criticised for methodological errors, and the results were summarized in a review article published in 1993.[62]
Improvements in mortality due to screening are hard to measure; similar difficulty exists in measuring the impact of Pap smear testing on cervical cancer, though worldwide, the impact of that test is likely enormous. Nationwide mortality due to cancer before and after the institution of a screening test is a surrogate indicator about the effectiveness of screening, and results of mammography are favorable.
Normal (left) versus cancerous (right) mammography image.The U.S. National Cancer Institute recommends screening mammography every one to two years beginning at age 40.[63] In the UK, women are invited for screening once every three years beginning at age 50. Women with one or more first-degree relatives (mother, sister, daughter) with premenopausal breast cancer should begin screening at an earlier age. It is usually suggested to start screening at an age that is 10 years less than the age at which the relative was diagnosed with breast cancer.
A clinical practice guideline by the US Preventive Services Task Force recommended "screening mammography, with or without clinical breast examination (CBE), every 1 to 2 years for women aged 40 and older."[64] The Task Force gave a grade B recommendation.[49][verification needed]
In 2005, 67.9% of all U.S. women age 40–64 had a mammogram in the past two years (74.5% of women with private health insurance, 56.1% of women with Medicaid insurance, 38.1% of currently uninsured women, and 32.9% of women uninsured for > 12 months).[65]
[edit] Criticisms of screening mammography Several scientific groups however have expressed concern about the public's perceptions of the benefits of breast screening.[66] In 2001, a controversial review published in The Lancet claimed that "there is no reliable evidence that screening for breast cancer reduces mortality".[67][68]The Cochrane Collaboration concluded, "for every 2000 women invited for screening throughout 10 years, one will have her life prolonged. In addition, 10 healthy women, who would not have been diagnosed if there had not been screening, will be diagnosed as breast cancer patients and will be treated unnecessarily. It is thus not clear whether screening does more good than harm."[69]
False positives are a major problem of mammographic breast cancer screening. Data reported in the UK Million Woman Study indicates that if 134 mammograms are performed, 20 women will be called back for suspicious findings, and four biopsies will be necessary, to diagnose one cancer. Recall rates are higher in the U.S. than in the UK.[70] The contribution of mammography to the early diagnosis of cancer is controversial, and for those found with benign lesions, mammography can create a high psychological and financial cost.
[edit] Mammography in women less than 50 years old Part of the difficulty in interpreting mammograms in younger women stems from the problem of breast density. Radiographically, a dense breast has a preponderance of glandular tissue, and younger age or estrogen hormone replacement therapy contribute to mammographic breast density. After menopause, the breast glandular tissue gradually is replaced by fatty tissue, making mammographic interpretation much more accurate. Some authors speculate that part of the contribution of estrogen hormone replacement therapy to breast cancer mortality arises from the issue of increased mammographic breast density. Breast density is an independent adverse prognostic factor on breast cancer prognosis.
A systematic review by the American College of Physicians concluded "Although few women 50 years of age or older have risks from mammography that outweigh the benefits, the evidence suggests that more women 40 to 49 years of age have such risks".[71].
A report released November 27, 2007 by the Journal of the National Cancer Institute showed that the formula doctors use to calculate a woman's risk of breast cancer underestimates the danger for black women most of the time and especially for those age 50 and older — the age when they are most likely to benefit from screening tests and protective drugs, according to the first major reassessment of the widely used tool.[72]
[edit] Enhancements to mammography CAD is especially established in US and the Netherlands. It is used in addition to the human evaluation of the diagnostician.
[edit] Breast MRI Magnetic resonance imaging (MRI) has been shown to detect cancers not visible on mammograms, but has long been regarded to have disadvantages. For example, although it is 27-36% more sensitive, it is less specific than mammography.[73] As a result, MRI studies will have more false positives (up to 5%), which may have undesirable financial and psychological costs. It is also a relatively expensive procedure, and one which requires the intravenous injection of a chemical agent to be effective. Proposed indications for using MRI for screening include:[74]
Strong family history of breast cancer Patients with BRCA-1 or BRCA-2 tumour suppressor gene mutations Evaluation of women with breast implants History of previous lumpectomy or breast biopsy surgeries Axillary metastasis with an unknown primary tumor Very dense or scarred breast tissue However, two studies published in 2007 demonstrated the strengths of MRI-based screening:
In March 2007, an article published in the New England Journal of Medicine demonstrated that in 3.1% of patients with breast cancer, whose contralateral breast was clinically and mammographically tumor-free, MRI could detect breast cancer. Sensitivity for detection of breast cancer in this study was 91%, specificity 88%.[75] In August 2007, an article published in The Lancet compared MRI breast cancer screening to conventional mammographic screening in 7,319 women. MRI screening was highly more sensitive (97% in the MRI group vs. 56% in the mammography group) in recognizing early high-grade Ductal Carcinoma in situ (DCIS), the most important precursor of invasive carcinoma. Despite the high sensitivity, MRI screening had a positive predictive value of 52%, which is totally accepted for cancer screening tests.[76] The author of a comment published in the same issue of The Lancet concludes that "MRI outperforms mammography in tumour detection and diagnosis."[77]
[edit] Breast self-exam Breast self-examination (BSE) was widely discussed in the 1990s as a useful modality for detecting breast cancer at an earlier stage of presentation. A large clinical trial in China reduced enthusiasm for breast self-exam. In the trial, reported in the Journal of the National Cancer Institute first in 1997 and updated in 2002, 132,979 female Chinese factory workers were taught by nurses at their factories to perform monthly breast self-exam, while 133,085 other workers were not taught self-exam. The women taught self-exam tended to detect more breast nodules, but their breast cancer mortality rate was no different from that of women in the control group. In other words, women taught breast self-exam were mostly likely to detect benign breast disease, but were just as likely to die of breast cancer.[78] In 2003, the American Cancer Society relegated structured BSE to an 'optional' method of detecting breast cancer, citing self awareness as more important than structured self exams based on recent research.[26]
[edit] Genetic testing A clinical practice guideline by the US Preventive Services Task Force :[64]
"recommends against routine referral for genetic counseling or routine breast cancer susceptibility gene (BRCA) testing for women whose family history is not associated with an increased risk for deleterious mutations in breast cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2)" The Task Force gave a grade D recommendation.[49][verification needed] "recommends that women whose family history is associated with an increased risk for deleterious mutations in BRCA1 or BRCA2 genes be referred for genetic counseling and evaluation for BRCA testing." The Task Force gave a grade B recommendation.[49][verification needed] The Task Force noted that about 2% of women have family histories that indicate increased risk as defined by:
For non–Ashkenazi Jewish women, any of the following: "2 first-degree relatives with breast cancer, 1 of whom received the diagnosis at age 50 years or younger" "3 or more first- or second-degree relatives with breast cancer regardless of age at diagnosis" "both breast and ovarian cancer among first- and second- degree relatives" "a first-degree relative with bilateral breast cancer" "a combination of 2 or more first- or second-degree relatives with ovarian cancer regardless of age at diagnosis" "a first- or second-degree relative with both breast and ovarian cancer at any age" "a history of breast cancer in a male relative." "For women of Ashkenazi Jewish heritage, an increased-risk family history includes any first-degree relative (or 2 second-degree relatives on the same side of the family) with breast or ovarian cancer."
[edit] Diagnosis This section does not cite any references or sources. (October 2007) Please improve this section by adding citations to reliable sources. Unverifiable material may be challenged and removed.
Breast cancer is diagnosed by the examination of surgically removed breast tissue. A number of procedures can obtain tissue or cells prior to definitive treatment for histological or cytological examination. Such procedures include fine-needle aspiration, nipple aspirates, ductal lavage, core needle biopsy, and local surgical excision. These diagnostic steps, when coupled with radiographic imaging, are usually accurate in diagnosing a breast lesion as cancer. Occasionally, pre-surgical procedures such as fine needle aspirate may not yield enough tissue to make a diagnosis, or may miss the cancer entirely. Imaging tests are sometimes used to detect metastasis and include chest X-ray, bone scan, Cat scan, MRI, and PET scanning. While imaging studies are useful in determining the presence of metastatic disease, they are not in and of themselves diagnostic of cancer. Only microscopic evaluation of a biopsy specimen can yield a cancer diagnosis. Ca 15.3 (carbohydrate antigen 15.3, epithelial mucin) is a tumor marker determined in blood which can be used to follow disease activity over time after definitive treatment. Blood tumor marker testing is not routinely performed for the screening of breast cancer, and has poor performance characteristics for this purpose.
[edit] Staging It has been suggested that this section be split into a new article entitled Breast cancer staging. (Discuss)
Breast cancer is staged according to the TNM system, updated in the AJCC Staging Manual, now on its sixth edition. Prognosis is closely linked to results of staging, and staging is also used to allocate patients to treatments both in clinical trials and clinical practice. The information for staging is as follows:
TX: Primary tumor cannot be assessed. T0: No evidence of tumor. Tis: Carcinoma in situ, no invasion T1: Tumor is 2 cm or less T2: Tumor is more than 2 cm but not more than 5 cm T3: Tumor is more than 5 cm T4: Tumor of any size growing into the chest wall or skin, or inflammatory breast cancer
NX: Nearby lymph nodes cannot be assessed N0: Cancer has not spread to regional lymph nodes. N1: Cancer has spread to 1 to 3 axillary or one internal mammary lymph node N2: Cancer has spread to 4 to 9 axillary lymph nodes or multiple internal mammary lymph nodes N3: One of the following applies:
Cancer has spread to 10 or more axillary lymph nodes, or Cancer has spread to the lymph nodes under the clavicle (collar bone), or Cancer has spread to the lymph nodes above the clavicle, or Cancer involves axillary lymph nodes and has enlarged the internal mammary lymph nodes, or Cancer involves 4 or more axillary lymph nodes, and tiny amounts of cancer are found in internal mammary lymph nodes on sentinel lymph node biopsy.
MX: Presence of distant spread (metastasis) cannot be assessed. M0: No distant spread. M1: Spread to distant organs, not including the supraclavicular lymph node, has occurred
Summary of stages:
Stage 0 - Carcinoma in situ Stage I - Tumor (T) does not involve axillary lymph nodes (N). Stage IIA – T 2-5 cm, N negative, or T <2 cm and N positive. Stage IIB – T > 5 cm, N negative, or T 2-5 cm and N positive (< 4 axillary nodes). Stage IIIA – T > 5 cm, N positive, or T 2-5 cm with 4 or more axillary nodes Stage IIIB – T has penetrated chest wall or skin, and may have spread to < 10 axillary N Stage IIIC – T has > 10 axillary N, 1 or more supraclavicular or infraclavicular N, or internal mammary N. Stage IV – Distant metastasis (M) Breast lesions are examined for certain markers, notably sex steroid hormone receptors. About two thirds of postmenopausal breast cancers are estrogen receptor positive (ER+) and progesterone receptor positive (PR+).[79] Receptor status modifies the treatment as, for instance, only ER-positive tumors, not ER-negative tumors, are sensitive to hormonal therapy.
The breast cancer is also usually tested for the presence of human epidermal growth factor receptor 2, a protein also known as HER2, neu or erbB2. HER2 is a cell-surface protein involved in cell development. In normal cells, HER2 controls aspects of cell growth and division. When activated in cancer cells, HER2 accelerates tumor formation. About 20-30% of breast cancers overexpress HER2. Those patients may be candidates for the drug trastuzumab, both in the postsurgical setting (so-called "adjuvant" therapy), and in the metastatic setting.[80]
[edit] Treatment Main article: Breast cancer treatment The mainstay of breast cancer treatment is surgery when the tumor is localized, with possible adjuvant hormonal therapy (with tamoxifen or an aromatase inhibitor), chemotherapy, and/or radiotherapy. At present, the treatment recommendations after surgery (adjuvant therapy) follow a pattern. This pattern is subject to change, as every two years, a worldwide conference takes place in St. Gallen, Switzerland, to discuss the actual results of worldwide multi-center studies. Depending on clinical criteria (age, type of cancer, size, metastasis) patients are roughly divided to high risk and low risk cases, with each risk category following different rules for therapy. Treatment possibilities include radiation therapy, chemotherapy, hormone therapy, and immune therapy.
In planning treatment, doctors can also use PCR tests like Oncotype DX or microarray tests like MammaPrint that predict breast cancer recurrence risk based on gene expression. In February 2007, the MammaPrint test became the first breast cancer predictor to win formal approval from the Food and Drug Administration. This is a new gene test to help predict whether women with early-stage breast cancer will relapse in 5 or 10 years, this could help influence how aggressively the initial tumor is treated.[81]
[edit] Prognosis This section does not cite any references or sources. (October 2007) Please improve this section by adding citations to reliable sources. Unverifiable material may be challenged and removed.
A prognosis is the medical team's "best guess" in how cancer will affect a patient. There are many prognostic factors associated with breast cancer: staging, tumour size and location, grade, whether disease is systemic (has metastasized, or traveled to other parts of the body), recurrence of the disease, and age of patient.
Stage is the most important, as it takes into consideration size, local involvement, lymph node status and whether metastatic disease is present. The higher the stage at diagnosis, the worse the prognosis. Larger tumours, invasiveness of disease to lymph nodes, chest wall, skin or beyond, and aggressiveness of the cancer cells raise the stage, while smaller tumours, cancer-free zones, and close to normal cell behaviour (grading) lower it.
Grading is based on how cultured biopsied cells behave. The closer to normal cancer cells are, the slower their growth and a better prognosis. If cells are not well differentiated, they appear immature, divide more rapidly, and tend to spread. Well differentiated is given a grade of 1, moderate is grade 2, while poor or undifferentiated is given a higher grade of 3 or 4 (depending upon the scale used).
Younger women tend to have a poorer prognosis than post-menopausal women due to several factors. Their breasts are active with their cycles, they may be nursing infants, and may be unaware of changes in their breasts. Therefore, younger women are usually at a more advanced stage when diagnosed.
The presence of estrogen and progesterone receptors in the cancer cell, while not prognostic, is important in guiding treatment. Those who do not test positive for these specific receptors will not respond to hormone therapy.
Likewise, HER2/neu status directs the course of treatment. Patients whose cancer cells are positive for HER2/neu have more aggressive disease and may be treated with trastuzumab, a monoclonal antibody that targets this protein.
[edit] Psychological aspects of diagnosis and treatment The emotional impact of cancer diagnosis, symptoms, treatment, and related issues can be severe. Most larger hospitals are associated with cancer support groups which can help patients cope with the many issues that come up in a supportive environment with other people with experience with similar issues. Online cancer support groups are also very beneficial to cancer patients, especially in dealing with uncertainty and body-image problems inherent in cancer treatment.
Not all breast cancer patients experience their illness in the same manner. Factors such as age can have a significant impact on the way a patient copes with a breast cancer diagnosis. For example, a recent study conducted by researchers at the College of Public Health of the University of Georgia showed that older women may face a more difficult recovery from breast cancer than their younger counterparts.[82] As the incidence of breast cancer in women over 50 rises and survival rates increase, breast cancer is increasingly becoming a geriatric issue that warrants both further research and the expansion of specialized cancer support services tailored for specific age groups.[83]
[edit] Racial disparities in diagnosis and treatment It has been suggested that this article or section be merged with Epidemiology and etiology of Breast cancer and Breast cancer treatment (Discuss)
Several studies have found that black women in the U.S. are more likely to die from breast cancer even though white women are more likely to be diagnosed with the disease. Even after diagnosis, black women are less likely to get treatment compared to white women.[84][85][86] Scholars have advanced several theories for the disparities, including inadequate access to screening, reduced availability of the most advanced surgical and medical techniques, or some biological characteristic of the disease in the African American population.[87] Some studies suggest that the racial disparity in breast cancer outcomes may reflect cultural biases more than biological disease differences.[88] Research is currently ongoing to define the contribution of both biological and cultural factors.[89][85]
[edit] Metastasis Most people understand breast cancer as something that happens in the breast. However it can metastasise (spread) via lymphatics to nearby lymph nodes, usually those under the arm. That is why surgery for breast cancer always involves some type of surgery for the glands under the arm — either axillary clearance, sampling, or sentinel node biopsy.
Breast cancer can also spread to other parts of the body via blood vessels or the lymphatic system. So it can spread to the lungs, pleura (the lining of the lungs), liver, brain, and most commonly to the bones.[90] Seventy percent of the time that breast cancer spreads to other locations, it spreads to bone, especially the vertebrae and the long bones of the arms, legs, and ribs. Breast cancer cells "set up house" in the bones and form tumors. Usually when breast cancer spreads to bone, it eats away healthy bone, causing weak spots, where the bones can break easily. That is why breast cancer patients are often seen wearing braces or using a wheelchair, and have aching bones.
When breast cancer is found in bones, it has usually spread to more than one site. At this stage, it is treatable, often for many years, but it is not curable. Like normal breast cells, these tumors in the bone often thrive on female hormones, especially estrogen. Therefore treatment with medicines that lower estrogen levels may be prescribed.
[edit] History This section does not cite any references or sources. (October 2007) Please improve this section by adding citations to reliable sources. Unverifiable material may be challenged and removed.
Breast cancer may be one of the oldest known forms of cancer tumors in humans. The oldest description of cancer was discovered in Egypt and dates back to approximately 1600 BC. The Edwin Smith Papyrus describes 8 cases of tumors or ulcers of the breast that were treated by cauterization.The writing says about the disease, "There is no treatment."[91] For centuries, physicians described similar cases in their practises, with the same sad conclusion. It wasn't until doctors achieved greater understanding of the circulatory system in the 17th century that they could establish a link between breast cancer and the lymph nodes in the armpit. The French surgeon Jean Louis Petit (1674-1750) and later the Scottish surgeon Benjamin Bell (1749-1806) were the first to remove the lymph nodes, breast tissue, and underlying chest muscle. Their successful work was carried on by William Stewart Halsted who started performing mastectomies in 1882. He became known for his Halsted radical mastectomy, a surgical procedure that remained popular up to the 1970s.
[edit] Cultural references In the month of October, breast cancer is recognized by survivors, family and friends of survivors and/or victims of the disease.[92] A pink ribbon is worn to recognize the struggle that sufferers face when battling the cancer.[93]
Pink for October is an initiative started by Matthew Oliphant, which asks that any sites willing to help make people aware of breast cancer, change their template or layout to include the color pink, so that when visitors view the site, they see that the majority of the site is pink. Then after reading a short amount of information about breast cancer, or being redirected to another site, they are aware of the disease itself.[94]
The patron saint of breast cancer is Saint Agatha of Sicily.[95]
[edit] See also List of notable breast cancer patients according to occupation List of notable breast cancer patients according to survival status List of breast carcinogenic substances Mammary tumor for breast cancer in other animals Breast reconstruction Alcohol and cancer Mammography Quality Standards Act National Breast Cancer Coalition National Comprehensive Cancer Network Breast Cancer Action Breakthrough Breast Cancer Barron Lerner (Physician) International Agency for Research on Cancer The Hormone Foundation Susan G. Komen for the Cure
[edit] References ^ American Cancer Society (September 26, 2007). What Is Breast Cancer?. Retrieved on 2008-02-03. ^ World Health Organization International Agency for Research on Cancer (June 2003). World Cancer Report. Retrieved on 2008-02-03. ^ a b c World Health Organization (February 2006). Fact sheet No. 297: Cancer. Retrieved on 2007-04-26. ^ Laurance, Jeremy. "Breast cancer cases rise 80% since Seventies", The Independent, 2006-09-29. Retrieved on 2006-10-09. ^ Breast Cancer: Statistics on Incidence, Survival, and Screening. Imaginis Corporation (2006). Retrieved on 2006-10-09. ^ a b c American Cancer Society (September 13, 2007). What Are the Key Statistics for Breast Cancer?. Retrieved on 2008-02-03. ^ a b c d American Cancer Society (2007). Cancer Facts & Figures 2007. Retrieved on 2007-04-26. ^ Espey DK, Wu XC, Swan J, et al (2007). "Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives". Cancer 110 (10): 2119–52. doi:10.1002/cncr.23044. PMID 17939129. Retrieved on 2007-11-09. ^ Society for Women's Health Research (2005-07-07). "Women's Fear of Heart Disease Has Almost Doubled in Three Years, But Breast Cancer Remains Most Feared Disease". Press release. Retrieved on 2007-10-15. ^ Leading Causes of Death for American Women 2004 (PDF). National Heart Lung and Blood Institute. Retrieved on 2007-10-15. ^ Male Breast Cancer Treatment - National Cancer Institute. National Cancer Institute (2006). Retrieved on 2006-10-16. ^ Breast Cancer in Men: Cancer Research UK. Cancer Research UK (2007). Retrieved on 2007-11-06. ^ American Cancer Society (September 27, 2007). What Are the Key Statistics About Breast Cancer in Men?. Retrieved on 2008-02-03. ^ Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics (Contemporary Cancer Research) by Anne M. Bowcock (1999) ^ Tumours of the breast and female genital organs, WHO classification of tumours, 2003, ISBN 92 832 2412 4 ^ Giordano SH, Hortobagyi GN (2003). "Inflammatory breast cancer: clinical progress and the main problems that must be addressed". Breast Cancer Res. 5 (6): 284-8. doi:10.1186/bcr608. PMID 14580242. Free Full Text. ^ a b c d Merck Manual of Diagnosis and Therapy (February 2003). Breast Disorders: Cancer. Retrieved on 2008-02-05. ^ eMedicine (August 23, 2006). Breast Cancer Evaluation. Retrieved on 2008-02-05. ^ National Cancer Institute (June 27, 2005). Paget's Disease of the Nipple: Questions and Answers. Retrieved on 2008-02-06. ^ National Cancer Institute (September 1, 2004). Metastatic Cancer: Questions and Answers. Retrieved on 2008-02-06. ^ Merk Manual of Diagnosis and Therapy (February 2003). Breast Disorders: Introduction. Retrieved on 2008-02-05. ^ Lane-Claypon, Janet Elizabeth (1926). A further report on cancer of the breast, with special reference to its associated antecedent conditions. London, Greater London: Her Majesty’s Stationery Office (HMSO). OCLC 14713036. ^ Alfredo Morabia (2004). A History of Epidemiologic Methods and Concepts. Boston: Birkhauser, 301-302. ISBN 3-7643-6818-7. Retrieved on 2007-12-31. ^ Cavalieri E, Chakravarti D, Guttenplan J, et al (2006). "Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention". Biochim. Biophys. Acta 1766 (1): 63-78. doi:10.1016/j.bbcan.2006.03.001. PMID 16675129. ^ Farlex (2005). ">immunological surveillance The Free Dictionary: Immunological Surveilliance. Retrieved on 2008-02-10. ^ a b c American Cancer Society (2005). Breast Cancer Facts & Figures 2005-2006. Retrieved on 2007-04-26. ^ Giordano, Sharon H; Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (May 2004). "Breast carcinoma in men". Cancer 101 (1): 51-57. American Cancer Society. ^ Individual Risk Factors. BreastCancer.org. Retrieved on 2007-03-11. ^ Yager JD; Davidson NE (2006). "Estrogen carcinogenesis in breast cancer". New Engl J Med 354 (3): 270-82. PMID 16421368. ^ Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, et al.. "Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study (WINS).". J Natl Cancer Inst 98 (24): 1767-1776. PMID 17179478. ^ Boffetta, Paolo; Hashibe, Mia; La Vecchia, Carlo; Zatonski, Witold; Rehm, Jürgen (2006-03-23). "The burden of cancer attributable to alcohol drinking". International Journal of Cancer 119 (4): 884–887. Wiley-Liss, Inc. doi:10.1002/ijc.21903. PMID 16557583. Retrieved on 2006-10-09. ^ BBC report Weight link to breast cancer risk ^ Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN (1995). "Proportion of breast cancer cases in the United States explained by well-established risk factors". J. Natl. Cancer Inst. 87 (22): 1681-5. PMID 7473816. Retrieved on 2007-05-26. ^ Venkitaraman, AR (2002). "cancer susceptibility and the functions of BRCA1 and BRCA2". Cell 108 (2): 171-82. ^ Rice S, Whitehead SA (2006). "Phytoestrogens and breast cancer--promoters or protectors?". Endocr. Relat. Cancer 13 (4): 995-1015. doi:10.1677/erc.1.01159. PMID 17158751. ^ Gikas PD, Mokbel K. (2005Phytoestrogens and the risk of breast cancer: a review of the literature. Int J Fertil Women's Med. ^ Mayo Clinic news release June 26 2001 "Folate Intake Counteracts Breast Cancer Risk Associated with Alcohol Consumption" ^ Boston University,Folate, Alcohol, and Cancer Risk ^ Bailey, L.B. Folate, methyl-related nutrients, alcohol and the MTHFR 677C -> T polymorphous affect cancer risk: intake recommendations. Journal of Nutrition, 2003, 133, 37485-37535 ^ Zhang S, Hunter D, Hankinson S, Giovannucci E, Rosner B, Colditz G, Speizer F, Willett W (1999). "A prospective study of folate intake and the risk of breast cancer". JAMA 281 (17): 1632-7. PMID 10235158. ^ Baglietto, Laura, et al. Does dietary folate intake modify effect of alcohol consumption on breast cancer risk? Prospective cohort study. British Medical Journal, August 8, 2005 ^ Jennings E. (1995). "Folic acid as a cancer preventing agent". Medical Hypotheses 45 (3): 297-303. PMID 8569555. ^ Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, Rosner BA, Speizer FE, Willett WC. (1998). "Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study". Annals of Internal Medicine 129 (7): 517-524. PMID 9758570. ^ name="Oldref_42">Freudenheim JL, Grahm S, Marshall JR, Haughey BP, Cholewinski S, Wilkinson G (1991). "Folate intake and carcinogenesis of the colon and rectum". International Journal of Epidemiology 20 (2): 368-374. PMID 1917236. ^ California Environmental Protection Agency: Air Resources Board, "Proposed Identification of Environmental Tobacco Smoke as a Toxic Air Contaminant" (June 24, 2005); on January 26, 2006, the Air Resources Board, following a lengthy review and public outreach process, determined ETS to be a Toxic Air Contaminant (TAC). ^ U.S. Department of Health and Human Services. "The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General", 2006 ^ J. Russo, I. Russo. "Molecular Basis of Breast Cancer: Prevention and Treatment," Springer, 2003 ^ Kauff N, Satagopan J, Robson M, Scheuer L, Hensley M, Hudis C, Ellis N, Boyd J, Borgen P, Barakat R, Norton L, Castiel M, Nafa K, Offit K (2002). "Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation". N Engl J Med 346 (21): 1609-15. PMID 12023992. ^ a b c d Guide to Clinical Preventive Services, Third Edition: Periodic Updates, 2000-2003. Agency for Healthcare Research and Quality. US Preventive Services Task Force. Retrieved on 2007-10-07. ^ (2002) "Chemoprevention of breast cancer: recommendations and rationale". Ann. Intern. Med. 137 (1): 56-8. PMID 12093249. ^ Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN (2002). "Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force". Ann. Intern. Med. 137 (1): 59-69. PMID 12093250. ^ Cummings SR, Eckert S, Krueger KA, et al (1999). "The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation". JAMA 281 (23): 2189-97. PMID 10376571. ^ Fisher B, Costantino JP, Wickerham DL, et al (2005). "Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study". J. Natl. Cancer Inst. 97 (22): 1652-62. doi:10.1093/jnci/dji372. PMID 16288118. ^ Fisher B, Costantino JP, Wickerham DL, et al (1998). "Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study". J. Natl. Cancer Inst. 90 (18): 1371-88. PMID 9747868. ^ Veronesi U, Maisonneuve P, Rotmensz N, et al (2007). "Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy". J. Natl. Cancer Inst. 99 (9): 727-37. doi:10.1093/jnci/djk154. PMID 17470740. ^ Cuzick J, Forbes JF, Sestak I, et al (2007). "Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial". J. Natl. Cancer Inst. 99 (4): 272-82. doi:10.1093/jnci/djk049. PMID 17312304. ^ Vogel VG, Costantino JP, Wickerham DL, et al (2006). "Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial". JAMA 295 (23): 2727-41. doi:10.1001/jama.295.23.joc60074. PMID 16754727. ^ Barrett-Connor E, Mosca L, Collins P, et al Raloxifene Use for The Heart (RUTH) Trial Investigators. (2006). "Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women". N. Engl. J. Med. 355 (2): 125-37. doi:10.1056/NEJMoa062462. PMID 16837676. ^ AFP.google.com, US approves Lilly's Evista for breast cancer prevention ^ Elwood J, Cox B, Richardson A. "The effectiveness of breast cancer screening by mammography in younger women.". Online J Curr Clin Trials Doc No 32: [23,227 words; 195 paragraphs]. PMID 8305999. ^ Fletcher S, Black W, Harris R, Rimer B, Shapiro S (1993). "Report of the International Workshop on Screening for Breast Cancer.". J Natl Cancer Inst 85 (20): 1644-56. PMID 8105098. ^ Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S (1993). "Report of the International Workshop on Screening for Breast Cancer". J. Natl. Cancer Inst. 85 (20): 1644-56. PMID 8105098. Retrieved on 2007-05-26. ^ NCI Statement on Mammography Screening - National Cancer Institute. Retrieved on 2007-09-11. ^ a b (2002) "Screening for breast cancer: recommendations and rationale". Ann. Intern. Med. 137 (5 Part 1): 344-6. PMID 12204019. ^ Ward E, Halpern M, Schrag N, Cokkinides V, DeSantis C, Bandi P, Siegel R, Stewart A, Jemal A (Jan-Feb 2008). "Association of insurance with cancer care utilization and outcomes". CA Cancer J Clin 58 (1). ^ "Women 'misjudge screening benefits'", BBC, Monday, 15 October, 2001. Retrieved on 2007-04-04. ^ Olsen O, Gøtzsche P (2001). "Cochrane review on screening for breast cancer with mammography". Lancet 358 (9290): 1340-2. PMID 11684218. ^ "New concerns over breast screening", BBC, Thursday, 18 October, 2001. Retrieved on 2007-04-04. ^ Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD001877. DOI: 10.1002/14651858.CD001877.pub2 ^ Smith-Bindman R, Ballard-Barbash R, Miglioretti DL, Patnick J, Kerlikowske K (2005). "Comparing the performance of mammography screening in the USA and the UK". Journal of medical screening 12 (1): 50-4. doi:10.1258/0969141053279130. PMID 15814020. ^ Armstrong K, Moye E, Williams S, Berlin JA, Reynolds EE (2007). "Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians". Ann. Intern. Med. 146 (7): 516-26. PMID 17404354. ^ Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, Sarto G, Rosenberg CA, Hubbell FA (2007). "Predicting risk of breast cancer in postmenopausal women by hormone receptor status.". J. Natl. Cancer Inst. 99 (22): 1695–705. doi:10.1093/jnci/djm224. PMID 18000216. Retrieved on 2007-12-02. ^ Hrung J, Sonnad S, Schwartz J, Langlotz C (1999). "Accuracy of MR imaging in the work-up of suspicious breast lesions: a diagnostic meta-analysis.". Acad Radiol 6 (7): 387-97. PMID 10410164. ^ Morrow M (2004). "Magnetic resonance imaging in breast cancer: one step forward, two steps back?". JAMA 292 (22): 2779-80. PMID 15585740. ^ Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, Peacock S, Smazal SF, Maki DD, Julian TB, DePeri ER, Bluemke DA, Schnall MD (2007). "MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer.". N Engl J Med. 356 (13): 1295-1303. PMID 17392300. ^ Kuhl CK, Schrading S, Bieling HB, Wardelmann E, Leutner CC, Koenig R, Kuhn W, Schild HH (2007). "MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study". The Lancet 370 (9586): 485-492. PMID. ^ Boetes C, Mann RM (2007). "Ductal carcinoma in situ and breast MRI". The Lancet 370 (9586): 459-460. PMID. ^ Thomas DB, Gao DL, Ray RM, et al (2002). "Randomized trial of breast self-examination in Shanghai: final results". J. Natl. Cancer Inst. 94 (19): 1445-57. PMID 12359854. ^ Rusiecki JA, Holford TR, Zahm SH, Zheng T. Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status. Cancer Detect Prev 2005;29:419-26 ^ accessed 1/30/07 cancer.gov ^ "FDA Approves New Breast Cancer Test". Associated Press, February 6, 2007. ^ Robb C, Haley WE, Balducci L, Extreman M, Perkins EA, Small BJ, Mortimer J. Impact of breast cancer survivorship on quality of life in older women. Critical Reviews in Oncology and Hematology. 2007 Apr; 62(1):84-91. ^ Robb C, Haley WE, Balducci L, Extreman M, Perkins EA, Small BJ, Mortimer J. Impact of breast cancer survivorship on quality of life in older women. Critical Reviews in Oncology and Hematology. 2007 Apr; 62(1):84-91. ^ Wisconsin Cancer Incidence and Mortality, 2000-2004 Wisconsin Department of Health and Family Services ^ a b Tammemagi CM (2007). "Racial/ethnic disparities in breast and gynecologic cancer treatment and outcomes". Curr. Opin. Obstet. Gynecol. 19 (1): 31–6. doi:10.1097/GCO.0b013e3280117cf8. PMID 17218849. ^ Hirschman J, Whitman S, Ansell D (2007). "The black:white disparity in breast cancer mortality: the example of Chicago". Cancer Causes Control 18 (3): 323–33. doi:10.1007/s10552-006-0102-y. PMID 17285262. ^ Breast cancer rates differ in races by Amanda Villa Wednesday, October 24, 2007. Badger Herald ^ Benjamin M, Reddy S, Brawley OW (2003). "Myeloma and race: a review of the literature". Cancer Metastasis Rev. 22 (1): 87–93. PMID 12716040. ^ Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID, Jatoi I (2007). "Racial disparities in breast cancer outcome: insights into host-tumor interactions". Cancer 110 (9): 1880–8. doi:10.1002/cncr.22998. PMID 17876835. ^ Lacroix M (2006). "Significance, detection and markers of disseminated breast cancer cells". Endocr Relat Cancer 13 (4): 1033-67. PMID 17158753. ^ The History of Cancer. American Cancer Society (2002-03-25). Retrieved on 2006-10-09. ^ Breast Cancer Awareness Month. Retrieved on 2008-01-04. ^ Pink Ribbon. Retrieved on 2008-01-04. ^ Pink for October. Retrieved on 2008-01-04. ^ Index of Saints. Catholic Forum. Retrieved on 2008-01-04. Arthur, Joyce (2002-03). Abortion and Breast Cancer — A Forged Link. The Humanist. Retrieved on 2007-11-03. Ressler, Kelly-Anne (2002-08). Information for GPs – Alcohol and cancer risk (PDF). Cancer Control Program. South Eastern Sydney and Illawarra Area Health Service. Retrieved on 2007-11-03. Surgery choices for women with early-stage Breast cancer (PDF). National Cancer Institute. United States Department of Health and Human Services. Retrieved on 2007-11-03. Napieralski, Julie A.; Carol Devine (1988-03). Alcohol and the Risk of Breast Cancer. Program on Breast Cancer and Environmental Risk Factors in New York State. Cornell University. Retrieved on 2007-11-03. Breast cancer incidence (most recent) by country. NationMaster.com. Retrieved on 2007-11-03. Radiology Info - Breast Cancer. Radiological Society of North America. Radiological Society of North America. Retrieved on 2007-11-03. Zuckerman, Diana. Mastectomy v. Lumpectomy: Who Decides?. National Research Center for Women & Families. National Research Center. Retrieved on 2007-11-03.
[edit] External links Wikimedia Commons has media related to: Breast cancerWikibooks Sexual Health has a page on the topic of Cancer#Breast CancerBreast cancer at the Open Directory Project Breast cancer at the Yahoo! Directory The Wiktionary definition of Breast cancer.
|
|
